Jeevan Scientific Technology FY26: Revenue Jumps 31% to ₹61.5 Cr, Profit Limps to ₹1.15 Cr, and the Market Pays 128x for the Combination

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1 — At a Glance

Jeevan Scientific Technology closed FY26 with consolidated revenue of ₹61.5 crore, up from ₹46.8 crore a year earlier — a 31% climb that is the loudest number on the page. The profit line is quieter: net profit of ₹1.15 crore, against ₹0.13 crore in FY25. The fourth quarter did most of the heavy lifting, posting ₹21.3 crore of sales and ₹4.29 crore of operating profit after a first half that ran at a loss.

Sitting beside that recovery is a market capitalisation of ₹147 crore and a P/E of 128 — a multiple that assumes a great deal about what a ₹1.15 crore profit becomes next. The equity base swelled during the year through preferential allotments, promoter holding fell from 38.05% to 30.25%, and cash flow from operations dropped to near zero even as the P&L improved.

So the year holds two stories at once: an operating business finding a second wind in the back half, and a balance sheet being reshaped by fresh capital, warrants, and an acquisition. The attention signal is the revenue jump. The worry signal is that the profit under it is small enough to fit in a rounding error. A business that raises capital faster than it earns it is telling you where the growth is expected to come from — and it isn’t operations yet.

Which half of the story is the real one? That’s the entry.

2 — Introduction

Incorporated in 1999 and listed on the BSE, Jeevan Scientific Technology is an independent clinical Contract Research Organization operating out of Hyderabad. It runs a single reportable segment — Clinical Research Services — which keeps its financial statements refreshingly free of the segment-note gymnastics larger CROs indulge in.

The recent history is one of expansion by allotment. During FY26 the company issued 40,85,000 fully paid equity shares to non-promoters, 30,00,000 convertible warrants to the promoter group, and 5,00,000 warrants to non-promoters under a preferential allotment, raising ₹3,074 lakh. It increased authorised capital, adopted a new memorandum, and pushed the equity share capital from ₹15.83 crore to ₹19.92 crore.

Alongside the fundraising, the group extended its structure. Nayas Laboratories Private Limited is now a 59.26% subsidiary, and Naya Pharma Private Limited an associate at 31.03%, with the company having approved investments, loans, and guarantees connected to Naya Pharma of up to ₹120 crore over the past two years. Management also cleared a US FDA remote regulatory assessment of its Hyderabad clinical pharmacology facility in early 2026, and completed a CDSCO inspection in June 2026 for adding beds to its bioequivalence centre.

The through-line: a small CRO that spent the year raising money and building a group around itself.

3 — Business Model: WTF Do They Even Do?

Jeevan Scientific gets paid to run the unglamorous machinery behind drug approvals. Three service lines carry the revenue. Clinical trial services cover patient PK trials, early and late-phase studies, post-marketing surveillance, and support for complex generics and biosimilars. Bioavailability and bioequivalence services handle the BA/BE studies — the “does the generic behave like the original” work — including food-effect, gender-effect, and pre/post-menopausal studies, with statistical analysis on SAS and WinNonlin. Pharmacovigilance rounds it out with data migration, literature searches, and audit support.

The physical plant is the moat, such as it is: a 20,000 sq. ft. research centre with 132 beds across four clinical pharmacology units, a bioanalytical lab with ten LC-MS/MS systems, and an NABL-accredited pathology lab. This is a business where regulators, not customers, decide whether you exist — which is why the FDA and CDSCO inspection notices are corporate events rather than footnotes. The June 2026 CDSCO inspection was specifically to add more beds, which tells you the constraint on a bed-based CRO: you can only run as many subjects as you can lie down.

Revenue historically skews domestic — roughly 74% India, 26% exports in FY24 — so this is a CRO with global accreditations earning most of its money at home. The export share has wandered between 24% and 43% over the decade, which is less a strategy than a symptom of a company small enough that a single large study moves the mix.

The model, in short: rent out beds, instruments, and regulatory credibility to pharma companies who’d rather not build their own. Capital-heavy, approval-gated, and only as scalable as the next inspection allows.

Does a 132-bed CRO with global accreditations grow into its ₹147 crore market cap, or does the bed count become the ceiling?

4 — Financials Overview

Figures are consolidated, in ₹ crore.

The fourth quarter more than doubled year-on-year revenue and swung operating profit from a ₹0.38